Analysis 11.6.
Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 6 Adverse events.
Adverse events
| Study | Description | Liraglutide 1.2 mg daily | Rosiglitazone 4 mg QD |
|---|---|---|---|
| L ‐ LEAD 1 Marre 2009 | withdrawal due to adverse events | 11 (5%) | 7 (3%) |
| L ‐ LEAD 1 Marre 2009 | overall adverse events | NR | NR |
| L ‐ LEAD 1 Marre 2009 | nausea | 24 (10.5%) | NR |
| L ‐ LEAD 1 Marre 2009 | vomiting | 10 (4.4%) | NR |
| L ‐ LEAD 1 Marre 2009 | diarrhoea | 18 (7.9%) | NR |
| L ‐ LEAD 1 Marre 2009 | serious adverse events (mostly judged to be unlikely to be related to study medication) | 9 (4%) | 7 (3%) |
| L ‐ LEAD 1 Marre 2009 | liraglutide auto‐antibodies | 9 to 13%, no effect on HbA1c | |
| L ‐ LEAD 1 Marre 2009 | deaths | None | None |
| L ‐ LEAD 1 Marre 2009 | pancreatitis | None | None |
| L ‐ LEAD 1 Marre 2009 |